Dr. Daniel Wallersdorfer, CEO Darwin AG

Dr. Daniel Wallersdorfer, CEO

Darwin AG
WKN: A3C35W | ISIN: DE000A3C35W0 | FSE: 7V0

Darwin AG is the parent company of the Austrian Novogenia GmbH, which is one of Europe’s leading biotechnology companies in the field of human genetics. The company’s own laboratory carries out genetic analyses that are used in the diagnosis, treatment and prevention of diseases as well as in the production of individually designed food supplements and cosmetics. Novogenia sees itself as a partner to doctors, therapists, pharmacists, nutritionists and fitness trainers. By analyzing the respective genetic predisposition of the patient or customer, the aim is to ensure the best possible treatment or care for their needs. Darwin AG was formed in September 2022 by changing its name from Novogenia Holding AG, which was founded in March 2021.

Speaker Details
Speaker Details
    Register for IIF-News